triamcinolon triamcinolone arthritis RA kenacort
Conditions
Interventions
Patients will receive 40 or 80 mg triamcinolone (Kenacort) to determine whether doubling the dose of corticosteroid injections in the treatment of arthritis in knee joint is more effective in the reli
Sponsors
Ziekenhuisgroep Twente
Zilvermeeuw 1,
7609 PP Almelo
+31(0)546 693 693
Eligibility
Inclusion criteria
Inclusion criteria: 1. Arthritis patients, RA or other causes of chronic arthritis (not osteoarthritis and not gout) with an indication for local injection with corticosteroid due to active arthritis in knee joint; 2. Patients should have stable anti-arthritic co-medication.
Exclusion criteria
Exclusion criteria: 1. Contraindication for local injection with corticosteroid (infection, relevant skin lesion, uncontrolled diabetes mellitus); 2. Chronic (>3 months) or current use of more than 10mg prednisolone or equivalent daily; 3. No informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with sustained good response. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Percentage of patients with good response in symptomatic relief at individual weekly time points (at t = 2,3,4,5,6,7,8,9,10,11 weeks); 2. Duration of response: Time lapsed between reaching good response; 3. Time to good response; 4. Asessment of arthritis activity by the trial physician; 5. VAS pain at t = 0 and t = 12 weeks; 6. Change of Range of Motion (ROM) on physical examination; 7. Change of swelling on physical examination, as determined by the trial physician on T=0 and T=12 weeks; 8. Change in patients health status. | — |
Contacts
Public ContactJ.W. Popma
Zilvermeeuw 1
Outcome results
None listed